Drug intelligence / Profile preview

SNT001

Development stage: Preclinical
Lead developer: Sintica Biotech
Modality: Peptides, Small Molecules

Overview

SNT001 is a small molecule peptidomimetic developed by Sintica Biotech that targets the CD271 receptor (also known as p75NTR or p75 neurotrophin receptor). It is designed to induce apoptosis in melanoma cells, specifically targeting melanoma-initiating cells and cancer stem cells which are often linked to tumor relapse, metastasis, and resistance to standard therapies. The drug is currently in preclinical development for the treatment of melanoma.

Targets

NGFR (p75NTR)

Beyond the preview

Go deeper on SNT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNT001.

Explore the full profile